目的 觀察芩香清解口服液聯(lián)合奧司他韋治療甲型流感的臨床療效。方法 選取2020年3月—2022年2月中國中醫(yī)科學(xué)院廣安門醫(yī)院收治的164例甲型流感患兒，按照隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組各82例。對(duì)照組口服磷酸奧司他韋顆粒，每次用藥劑量根據(jù)患兒體質(zhì)量而定，體質(zhì)量＜15 kg，30 mg/次；體質(zhì)量15～23 kg，45 mg/次；體質(zhì)量23～40 kg，60 mg/次；體質(zhì)量＞40 kg，75 mg/次；2次/d。治療組在對(duì)照組基礎(chǔ)上口服芩香清解口服液，每次用量根據(jù)患兒年齡段而定，1～3歲，5 mL/次；3～7歲，10 mL/次；7～14歲，15 mL/次；3次/d。兩組均連續(xù)治療5 d。觀察兩組臨床療效、退熱效果，咽痛、便秘的消失時(shí)間及病毒核酸轉(zhuǎn)陰率。比較治療前后兩組外周血中性粒細(xì)胞與淋巴細(xì)胞比值（NLR）和血清腫瘤壞死因子（TNF）-α、白細(xì)胞介素（IL）-8、C反應(yīng)蛋白（CRP）水平。結(jié)果 治療后，治療組總有效率97.6%，顯著高于對(duì)照組的89.0%（P＜0.05）。治療后，治療組退熱起效時(shí)間和完全退熱時(shí)間均較對(duì)照組顯著縮短，即刻退熱率68.3%較對(duì)照組52.4%顯著提高（P＜0.05）。治療后，治療組咽痛、便秘的消失時(shí)間均顯著短于對(duì)照組，病毒核酸轉(zhuǎn)陰率92.7%顯著高于對(duì)照組的81.7%（P＜0.05）。與治療前相比，治療后患者兩組外周血NLR和血清TNF-α、IL-8、CRP水平均顯著下降（P＜0.05）；且治療后，治療組外周血NLR和血清TNF-α、IL-8、CRP水平均顯著低于對(duì)照組（P＜0.05）。結(jié)論 芩香清解口服液聯(lián)合奧司他韋治療甲型流感具有顯著的退熱效果，能有效減輕患兒相關(guān)癥狀、控制病毒感染，并可進(jìn)一步緩解機(jī)體炎癥反應(yīng)，且安全性好。

Objective To observe the clinical efficacy of Qinxiang Qingjie Oral Liquid combined with oseltamivir in treatment of influenza A in children. Methods A total of 164 children with influenza A treated in Guang’anmen Hospital of China Academy of Chinese Medical Sciences from March 2020 to February 2022 were selected. All patients were divided into control group and treatment group according to the random number table method, with 82 cases in each group. Patients in the control group were po administered with Oseltamivir Phosphate Granules, each dose was determined according to the weight of the child, body weight < 15 kg, 30 mg/time. The body weight was 15-23 kg, 45 mg/time. The body weight was 23-40 kg, 60 mg/ time. Body weight > 40 kg, 75 mg/ time, twice daily. Patients in the treatment group were po administered with Qinxiang Qingjie Oral Liquid on the basis of the control group, the dosage was determined according to the age of the child, 1 to 3 years old, 5 mL/time; 3 to 7 years old, 10 mL/time; 7 to 14 years old, 15 mL/time, three times daily. Both groups were treated for 5 d. The clinical efficacy, antipyretic effect, disappearance time of sore throat, constipation and negative rate of viral nucleic acid were observed in the two groups. The ratio of neutrophils to lymphocytes (NLR) in peripheral blood, the levels of tumor necrosis factor (TNF) -α, interleukin (IL) -8 and C-reactive protein (CRP) in serum were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 97.6%, which was significantly higher than 89.0% of the control group (P < 0.05). After treatment, the antipyretic onset time and complete antipyretic time of the treatment group were significantly shorter than those of the control group, and the immediate antipyretic rate was 68.3%, which was significantly higher than that of the control group 52.4% (P < 0.05). After treatment, the disappearance time of sore throat and constipation in the treatment group was significantly shorter than that in the control group, and the negative rate of viral nucleic acid was 92.7%, which was significantly higher than 81.7% in the control group (P < 0.05). Compared with before treatment, the levels of peripheral blood NLR and serum TNF-α, IL-8 and CRP in the two groups were significantly decreased after treatment (P < 0.05). After treatment, the levels of peripheral blood NLR and serum TNF-α, IL-8 and CRP in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Qinxiang Qingjie Oral Liquid combined with oseltamivir has a significant antipyretic effect in treatment of influenza A, can effectively relieve the symptoms of patients, control the virus infection, and further relieve the body’s inflammatory response with good safety.

R974;R985